CorMedix Q4 rev $128.6M; FY2025 net income $163M; reiterates 2026 guidance

CorMedix Inc.

Q4 net revenue $128.6M ($91.2M DefenCath, $37.4M Melinta); net income $14.0M vs $13.5M YoY.
FY2025 total revenue $311.7M, pro forma $401.3M; net income $163.0M ($2.04 diluted EPS) vs prior year loss.
Q4 adjusted EBITDA $77.2M; 2026 guidance: revenue $300-320M, adj. EBITDA $100-125M.
Board approved $75M share repurchase program; cash and short-term investments $148.5M.
Phase 3 Rezzayo ReSPECT data expected Q2 2026; TPN catheter lock study target completion H1 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CorMedix Inc. updated its the fourth quarter and full year ended December 31, 2025 guidance (reaffirmed).

Period: the fourth quarter and full year ended December 31, 2025
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On March 5, 2026, CorMedix Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

CorMedix Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-023881

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.